Cargando…
Effects of SR141716A on Cognitive and Depression-Related Behavior in an Animal Model of Premotor Parkinson's Disease
A previous study from our laboratory revealed that moderate nigral dopaminergic degeneration caused emotional and cognitive deficits in rats, paralleling early signs of Parkinson's disease. Recent evidence suggests that the blockade of cannabinoid CB(1) receptors might be beneficial to alleviat...
Autores principales: | Tadaiesky, M. T., Dombrowski, P. A., Da Cunha, C., Takahashi, R. N. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
SAGE-Hindawi Access to Research
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2957172/ https://www.ncbi.nlm.nih.gov/pubmed/20976080 http://dx.doi.org/10.4061/2010/238491 |
Ejemplares similares
-
Effect of the Cannabinoid Receptor-1 antagonist SR141716A on human adipocyte inflammatory profile and differentiation
por: Murumalla, Ravi, et al.
Publicado: (2011) -
CB1 Receptor-Dependent and Independent Induction of Lipolysis in Primary Rat Adipocytes by the Inverse Agonist Rimonabant (SR141716A)
por: Müller, Günter A., et al.
Publicado: (2020) -
The cannabinoid ligands SR141716A and AM251 enhance human and mouse islet function via GPR55-independent signalling
por: Ruz-Maldonado, Inmaculada, et al.
Publicado: (2020) -
Cannabinoid receptor CB1 regulates STAT3 activity and its expression dictates the responsiveness to SR141716 treatment in human glioma patients' cells
por: Ciaglia, Elena, et al.
Publicado: (2015) -
Before the Tremor: Premotor Symptoms of Parkinson’s Disease
por: Konkel, Lindsey
Publicado: (2013)